Lophius Biosciences, has announced closing of an additional financing round totaling 1.4 million EUR.
All current financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF) as well as Bayernkapital participated in this financing round.
The funds will be used for the market introduction of the T-Track© CMV/EBV tests in the field of transplantation, for further development of a diagnostic test for the differential diagnosis of tuberculosis, as well as for the new development of a novel, blood-based multiple sclerosis test.
“We are very pleased to have been able to conclude this financing round with our existing investors in such a short time. Subsequent to the successful establishment of the company over the past year and the imminent conclusion of the test developments for our patented T-Track © CMV/EBV Tests, these new financial resources allow us to prepare for market entry of these tests from the beginning of 2012 with an effective team. Beyond this, we will now intensify the development of additional innovative diagnostic tests based on our patented technology platforms,” said Dr. Michael Lutz, CEO of Lophius Biosciences.
“With the aid of the financing round in the precious year Lophius Biosciences has been able to develop from an essentially academic research company into a small, highly innovative and fully integrated diagnostic company within a very short timeframe. We are absolutely convinced that the Lophius’ technologies and the products have a great potential to provide patients with large diagnostic benefits in our disease areas,” amended Bertram Gilka-Bötzow of S-Refit, Lophius Biosciences’ lead investor.